the Safety and Efficacy of Intravitreal Injection of Tpdelansbsalbac in Malignant Effusions.

Summary

This is a Phase I/II, open, first-in-human (FIH) study of Transebacillus in Patients with malignant pleural and abdominal effusions. It consists of Phase Ia to determine the Maximum tolerated dose (MTD) or Recommended Phase 2 dose (RP2D) of Transebacillus, and Phase Ib/II to explore and confirm the efficacy, safety and Tolerability.

Timeline

Start

2024-02-11

Primary completion

2024-04-01

Completion

2025-01-01

Drugs

Indications